Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience

Br J Haematol. 2020 Sep;190(5):e279-e282. doi: 10.1111/bjh.16935. Epub 2020 Aug 10.

Abstract

Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), emerged at the end of 2019 and caused an infection named COVID‐19 (Guan, Ni et al. 2020). Patients with compromised immune systems are at increased risk of complications but this risk is not precisely defined (Liang, Guan et al. 2020). Although age, gender, comorbidities and ethnicity are risk factors for adverse outcomes (Huang, Wang et al. 2020), various pre‐existing conditions, including haematological cancers, have also been reported to correlate with poor outcomes (Aries, Davies et al. 2020, He, Chen et al. 2020, Malard, Genthon et al. 2020, Martin‐Moro, Marquet et al. 2020, medRxiv 2020)

Keywords: COVID-19; SARS-CoV-2; haematological malignancies; lymphoid malignancies; myeloid malignancies; stem cell transplantation.

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Betacoronavirus / metabolism*
  • COVID-19
  • Cohort Studies
  • Coronavirus Infections* / blood
  • Coronavirus Infections* / etiology
  • Coronavirus Infections* / mortality
  • Coronavirus Infections* / therapy
  • Disease-Free Survival
  • Female
  • Hematologic Neoplasms* / blood
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / mortality
  • Hematologic Neoplasms* / therapy
  • Humans
  • Male
  • Middle Aged
  • Pandemics*
  • Pneumonia, Viral* / blood
  • Pneumonia, Viral* / etiology
  • Pneumonia, Viral* / mortality
  • Pneumonia, Viral* / therapy
  • RNA, Viral / blood*
  • SARS-CoV-2
  • Survival Rate
  • Time Factors

Substances

  • RNA, Viral